证券代码：600085 证券简称：同仁堂 公告编号：2023-034 北京同仁堂股份有限公司 关于控股股东对公司及控股子公司委托贷款 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、确定性和完整性承担法律责任。 重要内容提示： 控股股东中国北京同仁堂（集团）有限责任公司（以下简称同仁堂集团） 对北京同仁堂股份有限公司（以下简称公司）及控股子公司北京同仁堂科技发展 股份有限公司（以下简称同仁堂科技）、北京同仁堂商业投资集团有限公司（以 下简称同仁堂商业）以委托贷款形式拨付国有资本经营预算资金共计人民币 8,560 万元即将期满，公司及控股子公司将与同仁堂集团继续签订委托贷款协议， 同仁堂集团将以委托贷款形式拨付国有资本经营预算资金共计 8,560 万元给公司 及控股子公司，拨付资金将投入合同约定项目。 本次交易构成关联交易，但不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易事项经公司第九届董事会第二十三次会议及第九 届监事会第十六次会议审议通过，无需提交公司股东大会审议。 至本次关联交易为止，过去 12 个月内，同仁堂集 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 9,760,696,245.05, representing a 30.02% increase compared to the same period last year[13]. - The net profit attributable to shareholders was CNY 986,526,289.49, marking a 32.69% increase year-on-year[13]. - The net cash flow from operating activities was CNY 2,366,775,898.08, which is a 25.67% increase compared to the previous year[13]. - The total assets of the company at the end of the reporting period were CNY 29,058,986,690.05, reflecting a 7.41% increase from the end of the previous year[13]. - The net assets attributable to shareholders increased to CNY 12,412,636,216.71, a 5.10% rise compared to the previous year[13]. - Basic earnings per share for the first half of 2023 were CNY 0.719, up 32.66% from the same period last year[14]. - The weighted average return on net assets increased by 1.26 percentage points to 8.00%[14]. - The company reported a 33.22% increase in net profit after deducting non-recurring gains and losses, amounting to CNY 979,030,353.48[13]. - The company reported a total comprehensive income of CNY 1,657,262,716.38 for the first half of 2023, up from CNY 1,209,769,438.80 in the previous year, indicating a growth of 37.0%[104]. - The total profit for the first half of 2023 was CNY 1,864,010,649.65, compared to CNY 1,353,195,469.84 in the same period last year, reflecting a growth of 37.5%[105]. Operational Efficiency - The company is actively expanding its production capabilities through intelligent manufacturing, aiming to enhance efficiency and reduce energy consumption[21]. - The company has established multiple production bases across regions, ensuring a robust industrial cluster for its operations[21]. - The company is focused on high-quality development strategies, including the "High-Quality Development Strategy," "Fine Products Strategy," and "Large Varieties Strategy" to enhance governance and operational efficiency[23]. - The company has implemented a zero-defect quality management system and conducted comprehensive quality management enhancement activities, aiming to improve detection capabilities and establish a specialized inspection mechanism for key varieties[24]. - The company is enhancing its digital capabilities by implementing various digital management systems, including IoT digital production lines and a smart service robot to improve operational efficiency[26]. Market Position and Strategy - The company is positioned to capitalize on the growing demand for traditional Chinese medicine due to changing health perceptions and an aging population[20]. - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated by the increase in R&D spending[102]. - The company plans to expand its market presence and invest in new product development to enhance growth prospects in the upcoming quarters[91]. - The company is focusing on strategic investments and potential mergers and acquisitions to strengthen its market position[91]. Environmental Compliance - The company reported a total wastewater discharge of 15.99 thousand tons, with no exceedance of discharge standards[56]. - The subsidiary Tongrentang Technology reported a total wastewater discharge of 19.77 thousand tons, also with no exceedance of discharge standards[57]. - The company has established wastewater treatment facilities at all branches, which are operating normally and in compliance with regulations[58]. - Air pollution control facilities at all branches are functioning properly, ensuring compliance with emission standards[60]. - The company has implemented noise control measures at all branches, which are operating normally and meet the required standards[60]. - The company completed the 2022 carbon emission report and third-party verification on time, with plans for carbon quota compliance in the second half of 2023[68]. Governance and Shareholder Relations - The company held its first extraordinary general meeting on January 9, 2023, where the election of Ms. Yang Qingying as an independent director was approved[49]. - The annual general meeting on June 26, 2023, reviewed 23 proposals, including the 2022 financial settlement report and the profit distribution plan, all of which were approved[50]. - Ms. Yang Qingying was elected as an independent director and chair of the audit committee of the ninth board of directors[52]. - The company has established a corporate governance structure including a shareholders' meeting, board of directors, and supervisory board[125]. Financial Position - The total assets at the end of the current period amount to approximately 19,377.43 million, showing a strong asset base[117]. - The total liabilities at the end of the current period are approximately 6,964.80 million, indicating a manageable debt level[117]. - The total owner's equity at the end of the reporting period is CNY 17,224,761,877.36, with a capital reserve of CNY 1,353,754,682.55 and retained earnings of CNY 6,623,842,916.87[119]. - The company reported a net loss attributable to owners of CNY 438,870,483.84 for the first half of 2023, compared to a loss of CNY 397,726,375.98 in the same period last year[120]. Research and Development - R&D expenses grew by 41.26% to ¥101,573,460.06, reflecting increased investment in research and development[29]. - The company is actively exploring a quality control center operation model to enhance research management capabilities and ensure public medication safety through adverse reaction monitoring[25]. Risk Management - The company has not disclosed any significant risks that could materially affect its operations during the reporting period[3]. - The company adheres to strict quality control and compliance systems, enhancing its operational management and risk management frameworks[21].

证券代码：600085 证券简称：同仁堂 公告编号：2023-030 北京同仁堂股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 说明会召开的时间、地点 召开时间：2023 年 9 月 5 日（星期二） 上午 9:30-10:30 召开地点：上海证券报·中国证券网（http://roadshow.cnstock.com/） 召开方式：网络文字互动 1 会议召开时间：2023 年 9 月 5 日（星期二） 上午 9:30-10:30 会议召开地点：上海证券报·中国证券网（http://roadshow.cnstock.com/） 会议召开方式：网络文字互动 三、 参加人员 重要内容提示： 投资者可以在 2023 年 9 月 4 日下午 16:00 前将需要了解的情况和关注问题预 先发送到北京同仁堂股份有限公司（以下简称公司）邮箱，公司将在说明会上就 投资者普遍关注的问题进行回答。 公司于 2023 年 8 月 30 日披露了《2023 年半年度报告》，为便于广大投资 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥5,143,069,726.63, representing a 30.08% increase compared to ¥3,953,698,821.02 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥523,355,606.08, reflecting a 30.85% increase from ¥399,961,569.63 in the previous year[4] - The basic earnings per share for Q1 2023 was ¥0.382, an increase of 30.82% compared to ¥0.292 in the previous year[5] - Operating profit for Q1 2023 was ¥995,843,502.23, up 44.7% from ¥687,941,569.74 in Q1 2022[18] - The total comprehensive income for the first quarter of 2023 was CNY 772,106,058.66, an increase from CNY 548,283,148.97 in the same period of 2022, representing a growth of approximately 40.8%[19] Cash Flow and Assets - The net cash flow from operating activities reached ¥1,145,427,938.13, up 22.62% from ¥934,100,363.26 in the same period last year[5] - The company's cash and cash equivalents as of March 31, 2023, amount to approximately RMB 12.57 billion, an increase from RMB 11.62 billion at the end of 2022, reflecting a growth of about 8.15%[14] - Total current assets increased to approximately RMB 21.47 billion from RMB 20.56 billion, marking a growth of about 4.43% year-over-year[14] - The net increase in cash and cash equivalents for Q1 2023 was CNY 946,802,643.32, compared to CNY 780,999,899.77 in Q1 2022, showing an increase of approximately 21.2%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 67,051, with the largest shareholder, Beijing Tongrentang (Group) Co., Ltd., holding 719,308,540 shares, representing 52.45% of total shares[10] - The company has no pledged, marked, or frozen shares among its top shareholders, indicating a stable ownership structure[10] - The largest institutional investor, China Industrial Bank Co., Ltd., holds 53,320,470 shares, representing 3.89% of total shares[10] - The company has not reported any significant changes in its shareholder relationships or actions among major shareholders[11] Liabilities and Equity - Total liabilities rose to ¥8,689,204,417.95 in Q1 2023, compared to ¥8,590,423,576.47 in Q1 2022, marking an increase of 1.2%[16] - Shareholders' equity attributable to the parent company was ¥12,308,524,557.01, up 4.22% from ¥11,807,275,548.61 at the end of the previous year[5] - The company's total equity reached ¥19,225,133,163.58 in Q1 2023, an increase from ¥18,463,699,667.91 in Q1 2022, reflecting a growth of 4.1%[16] Operational Insights - The company reported a 30.08% increase in operating revenue due to increased demand in the pharmaceutical market and significant sales growth from subsidiaries[9] - The accounts receivable increased by 25.10% due to the management of customer credit limits, with the overall balance being reasonable and controllable[9] - Research and development expenses for Q1 2023 were ¥45,194,023.47, a 39.1% increase from ¥32,473,405.94 in Q1 2022[18] - Selling expenses in Q1 2023 amounted to ¥934,153,949.48, up 19.2% from ¥784,042,047.02 in Q1 2022[18] Inventory and Non-Current Assets - Inventory decreased to approximately RMB 6.40 billion from RMB 6.69 billion, a decline of about 4.31%[14] - The company reported a total non-current asset value of approximately RMB 6.05 billion as of March 31, 2023, compared to RMB 6.07 billion at the end of 2022, showing a slight decrease of about 0.33%[14] Future Outlook - Future outlook includes continued investment in R&D and market expansion strategies to sustain growth momentum[17] - The report does not indicate any new product launches or technological developments during the quarter[12]

Financial Performance - The company's operating revenue for 2022 was CNY 15,372,423,363.17, representing a 5.27% increase from CNY 14,603,100,739.78 in 2021[19] - The net profit attributable to shareholders of the listed company for 2022 was CNY 1,425,811,705.31, an increase of 16.17% compared to CNY 1,227,372,820.22 in 2021[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,398,575,430.62, up 15.67% from CNY 1,209,084,450.63 in the previous year[19] - Basic earnings per share rose by 16.20% to CNY 1.040 in 2022 compared to CNY 0.895 in 2021[20] - The weighted average return on equity increased by 0.72 percentage points to 12.71% in 2022 from 11.99% in 2021[20] - The gross profit margin improved to 48.80%, up by 1.18 percentage points compared to the previous year[32] - The total pre-tax compensation for the board members amounted to 1,067.37 million CNY for the reporting period[104] Cash Flow and Assets - The net cash flow from operating activities was CNY 3,094,296,284.27, a decrease of 9.69% from CNY 3,426,414,563.66 in 2021[19] - Total assets increased by 7.86% to CNY 27,044,491,889.50 in 2022 from CNY 25,072,835,362.31 in 2021[20] - The net cash flow from operating activities decreased by 9.69% year-on-year, amounting to 3,094.30 million yuan, mainly due to increased cash payments for goods and services[48] - The net increase in cash and cash equivalents was 1,735.40 million yuan, reflecting a 5.16% increase compared to the previous year[48] - Cash and cash equivalents amounted to ¥4,872,001,806.53 in 2022, an increase from ¥3,927,134,045.02 in 2021, marking a rise of about 24.0%[198] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.2 per 10 shares (including tax) based on a total share capital of 1,371,470,262 shares[4] - The company distributed a cash dividend of CNY 397,726,375.98, which accounts for 32.40% of the net profit attributable to ordinary shareholders in the consolidated financial statements[134] - The cash dividend per 10 shares is CNY 2.9, with no bonus shares or capital increase from reserves proposed[134] - The company has maintained a stable and continuous return policy for shareholders, considering future funding needs[132] Risk Management and Compliance - The company did not face any significant risks that could materially affect its operations during the reporting period[6] - The company has established a comprehensive integrity and compliance mechanism, including the formation of an Integrity and Compliance Committee and the implementation of risk assessment and feedback mechanisms[27] - The company emphasizes the importance of risk awareness regarding forward-looking statements in its report[5] - The company is facing risks related to industry policy changes, raw material supply fluctuations, and market instability, and is adapting its strategies accordingly[94] - The company is committed to maintaining high-quality standards in drug production and is enhancing its procurement processes to mitigate risks associated with raw material quality[94] Research and Development - Research and development expenses increased by 23.59% to CNY 217,446,263.51, indicating a significant investment in innovation[32] - The total R&D investment amounted to 3,660.83 million yuan, representing 2.38% of operating revenue, with a year-on-year increase of 14.50%[44] - The R&D team has made progress in new product development, including classic formulas and quality standards, with a focus on enhancing product value and addressing resource scarcity issues[65] - The company is actively pursuing internationalization of traditional Chinese medicine, particularly in the Hong Kong market, by enhancing marketing reforms and multi-channel promotion[28] - The company is focused on enhancing its product portfolio through strategic R&D initiatives and exploring market opportunities[65] Market Expansion and Retail Strategy - The company plans to continue focusing on market expansion and new product development to drive future growth[20] - As of the end of the reporting period, the company had 942 retail stores, focusing on enhancing operational efficiency and new retail technology to improve overall service levels[25] - The company has expanded its retail network to 73 stores globally, covering major countries and regions in Asia, Oceania, North America, and Europe[28] - The company is focusing on market demand and consumer trends, emphasizing marketing innovation and precise promotion strategies[57] Corporate Governance - The company has established an independent financial accounting department and a financial management system, ensuring independent financial decision-making[98] - The company’s management team is fully independent, with no overlapping positions with the controlling shareholder, ensuring transparency in personnel management[99] - The company’s governance structure includes various committees, such as the Strategic and Investment Committee and the Audit Committee, to ensure effective oversight[96] - The company has committed to enhancing its compliance management and legal support systems to foster a culture of integrity and compliance[99] Environmental Responsibility - The company has completed carbon emission verification and compliance tasks for 2021, demonstrating its commitment to environmental responsibility[27] - The company has invested CNY 20.84 million in environmental protection during the reporting period[142] - The company has achieved a total carbon emission of 20,516 tons for the year 2021, fulfilling its carbon emission quota in Beijing[153] - The company has implemented energy-saving management and new technologies to strengthen carbon emission management[155] Employee Development - The company emphasizes talent development through a diversified training system, focusing on management, professional technical, and high-skilled personnel[129] - The company has implemented a salary and assessment system for its management team to enhance performance motivation[136] - The company organizes annual continuing education training for professional technical personnel to strengthen their skills and knowledge[131] Shareholder Information - The total number of ordinary shareholders increased to 84,241 by the end of the reporting period, up from 77,597 at the end of the previous month[177] - The largest shareholder, China Beijing Tongrentang (Group) Co., Ltd., holds 719,308,540 shares, accounting for 52.45% of the total shares[178] - The company has no controlling shareholder or actual controller changes during the reporting period[182]

证券代码：600085 证券简称：同仁堂 公告编号：2023-012 北京同仁堂股份有限公司 关于召开 2022 年年度网络业绩说明会的预告公告 投资者可以在 2023 年 4 月 4 日下午 16:00 前将需要了解的情况和关注问题预 先发送到北京同仁堂股份有限公司（以下简称"同仁堂"或"公司"）邮箱，公 司将在说明会上就投资者普遍关注的问题进行回答。 公司于 2023 年 3 月 28 日披露了《同仁堂 2022 年年度报告》，为便于广大投 资者更全面深入地了解公司 2022 年年度经营成果及财务状况，公司决定于 2023 年 4 月 6 日通过上海证券报·中国证券网 http://roadshow.cnstock.com/召开"同仁 堂 2022 年年度网络业绩说明会"。 一、 说明会类型 本次投资者说明会以网络互动方式召开，公司将针对 2022 年年度的经营成 果及财务指标的具体情况等与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 召开时间：2023 年 4 月 6 日（星期四） 上午 9:30-10:30 召开地点：上海证券报·中国 ...